Biotechnology equipment market seen hitting $157.49 billion by 2030

The biotechnology equipment market is projected to grow from $74.83 billion in 2025 to $157.49 billion by 2030, according to The Business Research Company. The forecast points to demand from personalized medicine, lab automation, AI, robotics and genomics as North America holds the largest market share.

Why it matters: - Biotechnology equipment underpins genetic engineering, cell culture, molecular analysis, fermentation and drug development across life sciences, healthcare and pharmaceutical research. - The projected jump to $157.49 billion by 2030 signals sustained demand for tools that support personalized medicine, diagnostics and advanced lab workflows. - Growth in the market also reflects broader investment in pharmaceutical research and development and precision medicine infrastructure.

What happened: - The biotechnology equipment market is projected to rise from $74.83 billion in 2025 to $87.03 billion in 2026. - The market is forecast to reach $157.49 billion by 2030. - The Business Research Company published the market outlook on July 29, 2026. - North America held the largest share of the biotechnology equipment market in 2025.

The details: - The 2025-to-2026 expansion implies 16.3% growth. - The 2026-to-2030 forecast implies a 16.0% CAGR. - Growth factors in the earlier period included manual laboratory processes, limited automation, rising life science research and stronger demand for clinical diagnostics. - Future growth is expected to come from artificial intelligence and robotics in laboratories, higher spending on pharmaceutical R&D, broader use of high-throughput screening, and progress in genomics and precision medicine. - Other trends include more lab automation instruments, growing in vitro diagnostics applications, expanding clinical use of medical lasers, and more investment in bioreactors, fermenters and chromatography systems. - Personalized medicine is a major demand driver because treatment plans are increasingly tailored to a patient’s genetic makeup, lifestyle and environment. - Genetic and molecular profiling technologies are making those tailored treatment approaches more precise. - The Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Seven of those 2023 approvals were cancer treatments, and three targeted other conditions. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The forecast suggests the market is shifting from a research-support category to a more strategic layer of healthcare and biomanufacturing infrastructure. - The personalized medicine data points to a pipeline that is increasingly dependent on equipment capable of handling molecular-level analysis and more targeted production. - North America's lead indicates the region remains the center of demand, but the report's global coverage points to broader competition as lab automation and precision medicine spread.

What's next: - Adoption of AI-enabled lab systems and robotics is likely to be a central watchpoint for future market growth. - Investment in genomics, diagnostics and bioprocessing equipment should remain tied to the pace of personalized medicine adoption and pharmaceutical R&D spending. - The Business Research Company is promoting the full report and sample download for further market detail: Download a free sample and View the full report.

The bottom line: - Biotechnology equipment is on a high-growth path, with personalized medicine and lab automation emerging as the clearest demand engines through 2030.